Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

677
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
677
Protein and Protein Structure02:15

Protein and Protein Structure

83.4K
Proteins are one of the most abundant organic molecules in living systems and have the most diverse range of functions of all macromolecules. Proteins may be structural, regulatory, contractile, or protective. They may serve in transport, storage, or membranes; or they may be toxins or enzymes. Their structures, like their functions, vary greatly. They are all, however, amino acid polymers arranged in a linear sequence.
A protein's shape is critical to its function. For example, an enzyme...
83.4K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

1.5K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.5K
Amyloid Fibrils03:03

Amyloid Fibrils

10.8K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
10.8K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

480
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
480
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

293
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
293

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of early aggregation events by flexible peptidomimetics inhibits gelsolin amyloid formation.

International journal of biological macromolecules·2026
Same author

Optimizing grid preparation methods for TEM imaging of amyloid-forming proteins.

Biophysical chemistry·2026
Same author

Local Organization of Biological Membranes Modulates Tau-Lipid Interactions and Fibril formation.

JACS Au·2026
Same author

A β-hairpin mimic built on a fluorinated isoxazoline-β<sup>2,2</sup>-amino acid as a modulator of Tau protein aggregation.

Organic & biomolecular chemistry·2026
Same author

Neutrophil-targeted liposomal inhibition of PAD4-mediated NETosis in systemic lupus erythematosus.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Moving NMR infrastructures to remote access capabilities.

Progress in nuclear magnetic resonance spectroscopy·2026

Related Experiment Video

Updated: Oct 18, 2025

A11-positive &#946;-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.1K

β-Hairpin Peptide Mimics Decrease Human Islet Amyloid Polypeptide (hIAPP) Aggregation.

Jacopo Lesma1, Faustine Bizet1, Corentin Berardet1,2

  • 1BioCIS, CNRS, Université Paris-Saclay, Châtenay-Malabry, France.

Frontiers in Cell and Developmental Biology
|October 4, 2021
PubMed
Summary

Researchers designed new compounds to inhibit the aggregation of human islet amyloid polypeptide (hIAPP), a key factor in Type 2 Diabetes. These inhibitors show promise in preventing amyloid formation and reducing cell damage.

Keywords:
aggregationamyloidaza-peptidehIAPPpeptidomimeticstype 2 diabetesβ-hairpin

More Related Videos

Modeling Amyloid-&#946;42 Toxicity and Neurodegeneration in Adult Zebrafish Brain
10:01

Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain

Published on: October 25, 2017

11.5K
A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
06:34

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation

Published on: March 27, 2017

12.1K

Related Experiment Videos

Last Updated: Oct 18, 2025

A11-positive &#946;-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.1K
Modeling Amyloid-&#946;42 Toxicity and Neurodegeneration in Adult Zebrafish Brain
10:01

Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain

Published on: October 25, 2017

11.5K
A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
06:34

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation

Published on: March 27, 2017

12.1K

Area of Science:

  • Biochemistry and Molecular Biology
  • Protein Misfolding and Aggregation
  • Therapeutic Drug Design

Background:

  • Amyloid diseases, linked to aging, involve misfolded intrinsically disordered proteins (IDPs) that aggregate and cause cell death.
  • Type 2 Diabetes is associated with the aggregation of human islet amyloid polypeptide (hIAPP) into amyloid fibers in the pancreas.
  • Inhibiting protein aggregation is a therapeutic strategy, with prior success in targeting amyloid-beta (Aβ) aggregation in Alzheimer's disease.

Purpose of the Study:

  • To extend a previously successful strategy for inhibiting amyloid-beta aggregation to developing inhibitors for hIAPP aggregation.
  • To design, synthesize, and evaluate novel dynamic β-hairpin-like structures as hIAPP aggregation inhibitors.
  • To demonstrate the versatility of a rational design approach for creating selective inhibitors of amyloidogenic protein aggregation.

Main Methods:

  • Design and synthesis of dynamic β-hairpin-like structures using a piperidine-pyrrolidine β-turn inducer with varying peptide arms.
  • Conformational analysis and biophysical evaluations including Thioflavin-T fluorescence, transmission electron microscopy, capillary electrophoresis, and mass spectrometry.
  • Assessment of inhibitor efficacy in the presence of membrane models and their effect on hIAPP-induced membrane leakage.

Main Results:

  • The designed compounds, incorporating specific peptide arms derived from hIAPP, selectively modulated hIAPP aggregation.
  • Biophysical assays confirmed that the compounds inhibit both hIAPP oligomerization and fibrillization.
  • Inhibitors reduced aggregation near membrane models and significantly delayed hIAPP-induced membrane leakage.

Conclusions:

  • The rational design strategy is effective in creating selective inhibitors of hIAPP aggregation.
  • The developed compounds demonstrate potential therapeutic value for Type 2 Diabetes by targeting amyloid formation.
  • This approach offers a versatile platform for developing inhibitors against various amyloidogenic proteins.